Sirnaomics Publishes Data for Lead Candidate STP705 in Cancer Model as 2019 American Society of Clinical Oncology Annual Meeting Online Abstract

GAITHERSBURG, Md., May 16, 2019 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced the results of the effect of STP705 on the growth of HuCCt-1 (a human cholangiocarcinoma cell line) as a xenograft tumor in nude mice. The work is published as an online abstract at the 2019 American Society of Clinical Oncology Annual Meeting.

Abstract Title: Effect on tumor growth by TGF-β1/COX-2 siRNA combination product (STP705) in a human cholangiocarcinoma (HuCCT-1) xenograft tumor model in nude mice

Cholangiocarcinoma (CCA) is the second most common form of incurable hepatobiliary cancer and represents a massive health care burden worldwide with no effective treatment. Over expression of the genes for TGF-β1 and COX-2 have been well-characterized as playing key roles in tumorigenesis of CCA. STP705 consists of a combination of 2 siRNAs silencing the TGF-β1 and COX-2 genes delivered using a polypeptide nanoparticle delivery system based on Histidine-Lysine co-Polymer (HKP). We have demonstrated that STP705 inhibits the growth of HuCCt-1 xenograft tumors in nude mice (a human cholangiocarcinoma model) and the data is presented in the abstract.

Please click to view the complete abstract.

About Sirnaomics, Inc.
Sirnaomics, Inc., a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is a Delaware corporation headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China. The company's mission is to develop novel therapeutics to alleviate human suffering and advance patient care in areas of high unmet medical need. The guiding principles of the company are: Innovation, Global Vision with a Patient Centered focus. Members of the senior management team have a great deal of combined experience in the biopharmaceutical industry, financial, clinical and business management in both the USA and China. The company is supported by funding from institutional investors, corporate partnerships and government grants. Sirnaomics has developed a strong portfolio of intellectual property with an enriched product pipeline. The therapeutic areas of focus include oncology and anti-fibrotic therapeutics. Learn more at www.sirnaomics.com.

CONTACT:

Sirnaomics, Inc.
Michael Molyneaux MD MBA 
Chief Medical Officer
michaelmolyneaux@sirnaomics.com  

ICR Healthcare
Investors:
Stephanie Carrington
Tel: +1 646 277 1282 
Email: Stephanie.Carrington@icrinc.com  

Media: James Heins 
Tel: +1 203 682 8251
Email: James.Heins@icrinc.com  

View original content:http://www.prnewswire.com/news-releases/sirnaomics-publishes-data-for-lead-candidate-stp705-in-cancer-model-as-2019-american-society-of-clinical-oncology-annual-meeting-online-abstract-300852057.html

SOURCE Sirnaomics, Inc.